
![]() |
|||||||||||||
WJPR Citation
|
| All | Since 2020 | |
| Citation | 8502 | 4519 |
| h-index | 30 | 23 |
| i10-index | 227 | 96 |
ANTIHYPERTENSIVE DRUGS: AN ADVANCED COMPREHENSIVE REVIEW OF MECHANISMS, THERAPIES, AND CLINICAL INNOVATIONS
Snehal Genbhau Tengle*, Dr. Amita B. Dongar, Ms. Ashlesha Gaikwad
Abstract Hypertension is a leading global cause of morbidity and mortality.[4–6], contributing to cardiovascular, renal, and cerebrovascular disease. Antihypertensive pharmacotherapy continues to evolve, with new agents, combination strategies, and device-basedinterventions.[18–23] Precision medicine, pharmacogenomics.[26–28] and digital health technologies.[24–25] are reshaping individualized care. Overview of Major Antihypertensive Drug Classes (Section supported by Goodman & Gilman.[1], Katzung[2], Rang & Dale.[3] Keywords: Antihypertensive therapy, renin–angiotensin–aldosterone system, SGLT2 inhibitors, fixed dose combinations, resistant hypertension, renal denervation, pharmacogenomics. [Full Text Article] [Download Certificate] |
